Sensei Biotherapeutics (SNSE) Competitors $0.47 -0.01 (-2.87%) (As of 02:56 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends SNSE vs. ICCC, QTTB, GANX, DYAI, PASG, CVM, RLYB, SCYX, ACHL, and CLNNShould you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include ImmuCell (ICCC), Q32 Bio (QTTB), Gain Therapeutics (GANX), Dyadic International (DYAI), Passage Bio (PASG), CEL-SCI (CVM), Rallybio (RLYB), SCYNEXIS (SCYX), Achilles Therapeutics (ACHL), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry. Sensei Biotherapeutics vs. ImmuCell Q32 Bio Gain Therapeutics Dyadic International Passage Bio CEL-SCI Rallybio SCYNEXIS Achilles Therapeutics Clene ImmuCell (NASDAQ:ICCC) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking. Does the media favor ICCC or SNSE? In the previous week, ImmuCell had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for Sensei Biotherapeutics. ImmuCell's average media sentiment score of 1.43 beat Sensei Biotherapeutics' score of 0.00 indicating that ImmuCell is being referred to more favorably in the media. Company Overall Sentiment ImmuCell Positive Sensei Biotherapeutics Neutral Does the MarketBeat Community prefer ICCC or SNSE? ImmuCell received 94 more outperform votes than Sensei Biotherapeutics when rated by MarketBeat users. However, 79.41% of users gave Sensei Biotherapeutics an outperform vote while only 73.33% of users gave ImmuCell an outperform vote. CompanyUnderperformOutperformImmuCellOutperform Votes12173.33% Underperform Votes4426.67% Sensei BiotherapeuticsOutperform Votes2779.41% Underperform Votes720.59% Which has higher earnings and valuation, ICCC or SNSE? ImmuCell has higher revenue and earnings than Sensei Biotherapeutics. ImmuCell is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuCell$23.84M1.85-$5.78M-$0.50-9.90Sensei BiotherapeuticsN/AN/A-$34.10M-$1.19-0.41 Which has more volatility & risk, ICCC or SNSE? ImmuCell has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Do institutionals and insiders believe in ICCC or SNSE? 13.5% of ImmuCell shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 6.6% of ImmuCell shares are held by company insiders. Comparatively, 22.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is ICCC or SNSE more profitable? Sensei Biotherapeutics has a net margin of 0.00% compared to ImmuCell's net margin of -15.99%. ImmuCell's return on equity of -15.32% beat Sensei Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ImmuCell-15.99% -15.32% -8.81% Sensei Biotherapeutics N/A -53.86%-46.91% Do analysts recommend ICCC or SNSE? Sensei Biotherapeutics has a consensus target price of $4.33, suggesting a potential upside of 796.06%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than ImmuCell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryImmuCell beats Sensei Biotherapeutics on 10 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNSE vs. The Competition Export to ExcelMetricSensei BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.16M$6.84B$5.14B$9.30BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-0.4110.77135.3017.49Price / SalesN/A284.121,186.56136.36Price / CashN/A56.6540.4237.95Price / Book0.195.374.874.92Net Income-$34.10M$151.75M$118.61M$225.42M7 Day Performance11.17%-4.72%15.32%-1.20%1 Month Performance-3.67%2.09%15.26%7.09%1 Year Performance-22.00%16.12%34.42%22.83% Sensei Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNSESensei Biotherapeutics4.122 of 5 stars$0.47-2.9%$4.33+822.4%-26.7%$11.82MN/A-0.3940Positive NewsGap DownICCCImmuCell0.6592 of 5 stars$4.90-0.4%N/A+5.9%$43.67M$23.84M-9.8475Positive NewsGap DownQTTBQ32 Bio2.9076 of 5 stars$3.55-4.1%$29.86+741.0%N/A$43.24M$-6,651,000.00-0.2439Gap UpHigh Trading VolumeGANXGain Therapeutics3.0556 of 5 stars$1.630.0%$7.25+344.9%-32.8%$43.23M$50,000.00-1.4820Positive NewsDYAIDyadic International1.5277 of 5 stars$1.46-10.4%$6.00+311.0%-8.8%$43.20M$3.36M-6.007Negative NewsGap UpPASGPassage Bio2.9793 of 5 stars$0.69-9.0%$7.75+1,022.4%-10.7%$42.65MN/A0.00130CVMCEL-SCIN/A$0.67-3.5%N/A-71.9%$42.50MN/A-1.1943Negative NewsGap UpRLYBRallybio2.2417 of 5 stars$1.02-5.6%$9.75+855.9%-66.1%$42.32MN/A-0.6740SCYXSCYNEXIS0.9239 of 5 stars$1.07-6.1%N/A-30.6%$40.61M$8.57M-1.5460News CoverageACHLAchilles Therapeutics3.0811 of 5 stars$0.98-0.8%$4.00+307.3%+11.2%$40.36MN/A-0.60250CLNNClene3.8849 of 5 stars$4.80-3.0%$55.25+1,051.0%-48.1%$40.13M$650,000.00-0.94100 Related Companies and Tools Related Companies ICCC Alternatives QTTB Alternatives GANX Alternatives DYAI Alternatives PASG Alternatives CVM Alternatives RLYB Alternatives SCYX Alternatives ACHL Alternatives CLNN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNSE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
